Clinical Trial: Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Condition: Atherosclerotic Cardiovascular Disease
Study Type: Observational
Official Title: Impact of Optimal Pharmacotherapy on Plasma Lipid Profile and Qualitative Features of Atherosclerotic Plaques in Very-high Cardiovascular Risk Patients With Established Atherosclerotic Cardiovascular
Brief Summary:
Lipid accumulation, with mostly emphasized role of low-density lipoprotein cholesterol (LDL-C), is the pathogenetic cornerstone of atherosclerotic cardiovascular disease. Standard hypolipidemic therapy, based on statins and ezetimibe, does not always decrease LDL-C levels enough to achieve therapeutic goals. A novel and promising direction is inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, subsequently reducing LDL-C receptor degradation and increasing intracellular LDL-C…
Read more